| CASE REPORT |
|
| Year : 2022 | Volume
: 2
| Issue : 2 | Page : 422-423 |
|
|
Low-dose rifabutin-induced uveitis with premature occurrence: A case series of rare presentation
Sumedha Vats1, Mohini Agrawal2, S Srikanth3, Poninder Kumar3, Ranjit Goenka4
1 Department of Ophthalmology, Armed Forces Clinic, New Delhi, India
2 Department of Ophthalmology, Command Hospital, Pune, Maharashtra, India
3 Department of Ophthalmology, Armed Forces Medical College, Pune, Maharashtra, India
4 Department of Ophthalmology, Base Hospital, New Delhi, India
Correspondence Address:
Sumedha Vats
Department of Ophthalmology, Armed Forces Clinic, New Delhi
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijo.IJO_2814_21
|
|
|
Rifabutin is a known-drug prescribed for prophylaxis and treatment of Mycobacterium avium complex (MAC) and causes dose-related anterior uveitis in immunocompromised individuals, particularly, those infected with HIV. Previous studies have reported rifabutin-induced uveitis with high doses. It is infrequent with 300 mg/day or less; moreover, it takes weeks to months to develop. We report three HIV cases that on treatment with low-dose 300 mg rifabutin presented with anterior uveitis with early occurrence. Furthermore, one of the cases had rifabutin-induced panuveitis, another rarity. Thus, although rare, low-dose rifabutin-induced uveitis with early presentation should be kept as a differential diagnosis of unusual presentation of uveitis in HIV, early management of which prevents visual morbidity.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
